FibroBiologics opened higher at $1.01, compared with its previous close of $1.00. In the last trading session, the stock traded between $0.93 and $1.01. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in FibroBiologics is now worth
$ 0.16
Resulting in a loss of
$ 99.84 (99.84%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.04 (-4.20%)
Day High
$1.01
Day Low
$0.93
Day Open
$1.01
Prev Close
$1.00
Volume
32,472
1W Return
-2.45%
1M Return
-6.29%
3M Return
-6.47%
6M Return
-3.64%
1Y Return
-85.87%
Fundamentals
Market Cap ($ Mn)
6
PE Ratio
-
PB Ratio
1.89
PEG Ratio
-
ROE
-762.56%
ROCE
-472.92%
EPS (TTM)
$-0.68
Investment Returns
1 Week
-2.45%
1 Month
-6.29%
3 Months
-6.47%
6 Months
-3.64%
9 Months
-81.27%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
12Nov
FibroBiologics says portfolio now includes 170 issued patents
FibroBiologics reports **170 issued patents** and over **325 total patents** worldwide. Portfolio expanded from **124 issued patents** on December 31, 2025, to **170** by November 12, 2026. IP covers diverse pathways including wound healing, type 1 diabetes, osteoporosis, and cachexia. More than **50 patent families** protect both therapeutic applications and manufacturing techniques.
Today
19Oct
FibroBiologics reports FSdC spheroids best preserve disc height in preclinical study
FSdC spheroids preserved disc height better than other fibroblast approaches in a 12-week rabbit model. Data presented by Nikolay Bazhanov at the NASS 2026 Annual Meeting in San Antonio. FibroBiologics holds over 270 patents issued and pending for fibroblast-derived therapeutics.
24 days ago
7Oct
FibroBiologics files US patent for continuous GLP-1 peptide production
FibroBiologics Inc filed a US patent for engineered cells producing GLP-1, GIP, and GLP-2 peptides. Technology aims to replace weekly injections with a single administration of spheroids or organoids. Platform covers applications in diabetes, cancer, autoimmune diseases, and tissue regeneration. Patent includes safety features like inducible switches and immune-evasive modifications.
